BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260713T100000
DTEND;TZID=Europe/Brussels:20260713T110000
DTSTAMP:20260726T155015
CREATED:20260615T074916Z
LAST-MODIFIED:20260703T110803Z
UID:9672-1783936800-1783940400@www.europabio.org
SUMMARY:EFIB Den Haag Statement - A modernised European Union for Industrial Biotechnology
DESCRIPTION:EuropaBio’s EFIB Statement presents three clear asks for the European Union: \n\n\n\nAsk 1 – Modernising regulation and policy: A dedicated\, horizontal EU Regulation for Microorganisms \n\n\n\nAsk 2 – Education and awareness: Future-looking stakeholder engagement and Representation \n\n\n\nAsk 3 – Financing innovation: Delivering a mature funding and collaborative framework \n\n\n\nThese asks sit within a progressive legislative mandate for industrial biotechnology and microorganisms. It supports the translation of a competitiveness agenda into legislation that delivers the bioeconomy. \n\n\n\nJoin EuropaBio for a deep dive into the EFIB Statement and what it means for innovation and manufacturing in the European Union? \n\n\n\nAGENDA \n\n\n\nPresentation of the EFIB statement: Claire Skentelbery\, Director General\, EuropaBio \n\n\n\nFireside chat: Giovanni Colombo\, Group Senior Director Public Affairs\, dsm-firmenich and Board Member EuropaBio \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/efib-den-haag-statement-a-modernised-european-union-for-industrial-biotechnology/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/06/EFIB-2026-Den-Haag-Statement-Event-Banner-Website-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260701T093000
DTEND;TZID=Europe/Brussels:20260701T133000
DTSTAMP:20260726T155015
CREATED:20260505T073147Z
LAST-MODIFIED:20260519T114509Z
UID:9589-1782898200-1782912600@www.europabio.org
SUMMARY:EuropaBio Biomanufacturing Policy Summit 2026
DESCRIPTION:From legislation to impact for Europe \n\n\n\nBiomanufacturing lies at the heart of Europe’s future societal and entrepreneurial strength and is changing the business landscape for both emerging innovators and established industry champions. \n\n\n\nEuropaBio’s 4th Biomanufacturing Policy Summit will focus on how legislation delivers impact within a proactive Biomanufacturing strategy\, and how we establish EU targets for outcomes. It will also showcase the 2026 update of the EuropaBio WIfoR study ‘Measuring the Economic Footprint of the Biotechnology Industry in the European Union’ prior to full report launch in September. \n\n\n\nThe prize is globally competitive multi-sector biomanufacturing\, keeping pace with industrial transition in major global regions and securing Europe’s supply chains\, healthcare future\, decarbonisation and economic resilience. \n\n\n\nThis meeting will bring together EuropaBio Members\, representatives of key sectors\, plus national and EU stakeholders across institutions. \n\n\n\nThis event will be accessible by invitation only\, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org
URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2026/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/05/Event-Banner-EuropaBio-Biomanufacturing-Policy-Summit-2026.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260611T090000
DTEND;TZID=Europe/Brussels:20260611T133000
DTSTAMP:20260726T155015
CREATED:20260424T102431Z
LAST-MODIFIED:20260424T102433Z
UID:9607-1781168400-1781184600@www.europabio.org
SUMMARY:European Biotech Forum 2026
DESCRIPTION:EuropaBio is a proud sponsor of the European Biotech Forum 2026. \n\n\n\nBiotechnology is becoming a decisive capability for Europe’s competitiveness\, industrial resilience and strategic autonomy. But Europe enters the next institutional cycle with a fragmented policy landscape\, uneven regulatory capacity\, and persistent scale-up barriers. The Commission’s Biotech Communication I and Biotech Communication II set out an initial toolbox\, but fall short of an end-to-end industrial framework comparable to the US. The gap between ambition and execution remains significant. To what extent do these communications address the core challenges of Europe’s biotech sector? Where are the structural gaps that still block growth and industrial deployment? \n\n\n\n\nMore Info & Registration Here
URL:https://www.europabio.org/event/european-biotech-forum-2026/
CATEGORIES:EuropaBio,External,Healthcare Biotech,Industrial Biotech,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/04/Event-Banners-Website-1-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260414T143000
DTEND;TZID=Europe/Brussels:20260414T153000
DTSTAMP:20260726T155015
CREATED:20260309T135321Z
LAST-MODIFIED:20260309T143349Z
UID:9503-1776177000-1776180600@www.europabio.org
SUMMARY:The EU Biotech Act: Europe’s ambition for biotechnology
DESCRIPTION:Join Director General Sandra Gallina and EuropaBio to explore the EU Biotech Act proposal\, published in December 2025. \n\n\n\nThe webinar explores the Goal of the Act\, to boost innovation\, support development of biotech products and accelerate time-to-market\, making use of industrial enablers and regulatory simplification. \n\n\n\nThis webinar will introduce the drivers behind the Biotech Act proposal plus its diverse and ambitious mechanisms to boost EU biotech delivery. It will discuss how mechanisms might work and the interlink of the Act with the wider European Legislative landscape\, and its legislative pathway into action for the EU. \n\n\n\nWebinar delegates will have the opportunity to ask Director General Gallina questions during the event and EuropaBio will publish a summary for all participants. \n\n\n\nAGENDA \n\n\n\n\n\n\n\n\n14h30: Introduction – Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n\n\n\n\n\n\n14h40: The Biotech Act in focus – Director General Sandra Gallina\, DG Health and Food Safety\, European Commission: \n\n\n\n\n\nRegulatory streamlining and facilitation in health\, food and other biotech\n\n\n\nIndustrial enablers including High Impact Strategic Projects\, Boosting innovative biotech & biosimilars\, Access to Finance\, AI and Data\, Biosecurity & Defence\n\n\n\n\n15h10: Discussion and audience Q&A \n\n\n\n15h30: Close \n\n\n\nWho should attend? If you are active within biotechnology in any sector\, you should attend to understand what the Act means for you\, how you should be involved and what happens next. \n\n\n\nRegister below \n\n\n\n\nRegistration Here
URL:https://www.europabio.org/event/the-eu-biotech-act-europes-ambition-for-biotechnology/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/03/Event-Banners-Website-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260323T163000
DTEND;TZID=Europe/Brussels:20260323T180000
DTSTAMP:20260726T155015
CREATED:20260317T081056Z
LAST-MODIFIED:20260317T081058Z
UID:9523-1774283400-1774288800@www.europabio.org
SUMMARY:Special feature: Biotech Act Part I – Dr Claire Skentelbery\, Director General EuropaBio @ BIO-Europe Spring 2026
DESCRIPTION:Join our Director General Dr Claire Skentelbery at BIO-Europe Spring on the 23rd of March for an afternoon session dedicated to the EU Biotech Act Part 1. \n\n\n\nThe EU Biotech Act represents a landmark piece of legislation aimed at positioning Europe as a global leader in biotech. Structured in two parts\, the legislative program seeks to drive competitiveness across multiple sectors. Part I of the EU Biotech Act\, published in December 2025\, focuses on advancing health innovation. Key initiatives include accelerating clinical trials\, extending intellectual property protections\, launching a robust investment program\, and introducing strategic projects designed to achieve critical mass in applied innovation. Part II\, set to be unveiled in 2026\, will shift the focus toward maximising biomanufacturing across industries\, further strengthening Europe’s biotech ecosystem. \n\n\n\nThis feature session is dedicated to the Biotech Act part\, including a Keynote and Fireside Chat. \n\n\n\n16:30 Keynote presentation: Dr Claire Skentelbery\, Director General EuropaBio \n\n\n\n17:00 Fireside chat: Dr Claire Skentelbery in discussion with Dr Tilo Mandry\, Lead International Liaison Manager IGES \n\n\n\n17:15: Session: Special feature: Biotech Act Part I – What’s in it for me? Industry panel discussionPanelists:– Dr Morgane Rousselot\, Founder\, Chairwoman and CEO\, SeaBeLife Biotech– Dr Ann Belien\, Founder & CEO\, Rejuvenate Biomed (tbc)– Andreas Prenner\, Policy Officer\, European Commission– Dr Marjo Puumalainen\, International Director\, SwedenBIO– Dr Tilo Mandry\, Lead International Liaison Manager\, IGES (Moderator) \n\n\n\nThis panel continues the EU Biotech Act Special Feature: We will discuss what the Biotech Act means for biotech companies and Europe as a biotech investment location\, and how companies can best adapt to its provisions. \n\n\n\nThere are many questions about the Biotech Act:– How will industrial clinical research be accelerated and how will this affect the development of innovative therapies?– How will the Biotech Act impact the financing of innovative biotech start-ups?– Can cell and gene therapies now be developed more quickly by companies in the EU and brought to patients more easily?– What does the extension of intellectual property protection mean for biopharmaceutical companies in practice?– Is the Act sufficiently targeted at industry and where are the risk points?– And finally\, can the EU compete globally\, particularly with the US and China\, thanks to the Biotech Act?We will discuss these and many other important aspects with the panelists and the audience. \n\n\n\n18:00: Close \n\n\n\n\nMore Info Here
URL:https://www.europabio.org/event/special-feature-biotech-act-part-i-dr-claire-skentelbery-director-general-europabio-bio-europe-spring-2026/
CATEGORIES:Biomanufacturing Platform,EuropaBio,External,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Event-Banners-Website-38.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20260310T100000
DTEND;TZID=Europe/Brussels:20260310T110000
DTSTAMP:20260726T155015
CREATED:20260209T143814Z
LAST-MODIFIED:20260209T143816Z
UID:9448-1773136800-1773140400@www.europabio.org
SUMMARY:Navigating Biotech SME Funding: What's available\, How it works\, What's next for Europe
DESCRIPTION:Europe’s biotech sector continues to face significant financing challenges\, especially during growth and scale‑up. As the EU moves forward with the landmark Biotech Act\, this webinar explores the funding tools available today\, how companies can access them\, and what changes are needed to expand investment in European biotech. \n\n\n\nThe session will provide an overview of current EU public and blended finance options across the development pipeline\, explain how the European Investment Bank evaluates and supports biotech projects\, and offer first-hand insights from a biotech founder on securing funding from idea to market. It will also examine how upcoming EU initiatives could improve access to capital and attract more private investment. \n\n\n\nSpeakers include \n\n\n\nFelicitas Riedl\, Director of Innovation and Competitiveness at the European Investment Bank \n\n\n\nRaffael Wohlgensinger\, Founder & CEO\, Formo \n\n\n\nJessica Martinsson\, our moderator and CEO of SwedenBIO\, the Swedish Biotech Association \n\n\n\n\nRegistration Here
URL:https://www.europabio.org/event/navigating-biotech-sme-funding-whats-available-how-it-works-whats-next-for-europe/
CATEGORIES:EuropaBio,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2026/02/Navigating-Biotech-SME-Funding-Event-Banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20251015T120000
DTEND;TZID=Europe/Brussels:20251015T210000
DTSTAMP:20260726T155015
CREATED:20250505T110759Z
LAST-MODIFIED:20250814T132321Z
UID:9042-1760529600-1760562000@www.europabio.org
SUMMARY:Biotech & Biomanufacturing Policy Summit
DESCRIPTION:EuropaBio is pleased to host its third Summit focused on biotechnology & biomanufacturing. \n\n\n\nBiotechnology is a critical technology for Europe.  Delivery of innovation into market drives competitiveness\, security\, supply chain resilience plus societal and environmental goals.  Europe must be ambitious and globally aware\, with a focus on securing its biotechnology capability within fast changing global geopolitics. \n\n\n\nThe current Commission has a significant opportunity to set and deliver on the ambition needed. Legislation such as the Biotech Act\, plus the frameworks that we create for sectors including health\, agri-food and manufacturing. \n\n\n\nThe half day Summit brings together EuropaBio Members and stakeholders to understand the ambition needed for legislation\, how the EU and its Member States can deliver and recognition of global positioning needed. \n\n\n\nIt is supported by biotech product displays and EU projects\, plus evening networking reception. It will be followed by a Summit Statement and public webinar hosted in November. \n\n\n\nAgenda: \n\n\n\n12:30 Registration and lunch13:15 Welcome and Keynote session Summit keynotes bring Industry\, Parliament and Commission perspectives to Europe’s ambition for biotech and biomanufacturing and the policy framework currently in action. Commissioner Olivér Várhelyi – Commissioner for Health and Animal Welfare Markus Staempfli – EuropaBio Chair\, Vice President Europe Major Markets & Canada\, CSL Behring MEP Stine Bosse – MEP and co-chair EU Alliance of Biotech and Life Sciences14:00 Panel sessions The current legislative cluster impacting biotechnology and biomanufacturing is in focus for our panel discussions. Stakeholders from across industry\, policy and member states discuss what Europe’s ambition must be and how individual and aligned legislations can deliver.Panel 1 – Enabling EU markets How policy creates markets for biotech products and enables biomanufacturing processes.Panel 2 – Enhancing access How market pathways are vital for product and process commercial viability\, determining speed and scale of access and uptake.Panel 3 – Building the EU ecosystem How knowledge\, skills\, finance and infrastructure deliver on market potential for Europe.17:50 Pre-reception remarks18:00 Reception20:30 Close\n\n\n\nThis event will be accessible by invitation only\, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org
URL:https://www.europabio.org/event/biotech-biomanufacturing-policy-summit/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,National Associations,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/05/Event-Banner-Website-Biotech-Biomanufacturing-Policy-Summit.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250612T133000
DTEND;TZID=Europe/Brussels:20250612T143000
DTSTAMP:20260726T155015
CREATED:20250428T070156Z
LAST-MODIFIED:20250505T082148Z
UID:9012-1749735000-1749738600@www.europabio.org
SUMMARY:EFIB Brussels Statement – a competitive future for the EU
DESCRIPTION:The EFIB Brussels statement was published following the successful workshop that EuropaBio organised together with Genopole during the Bioket conference on 11 March. It looks ahead to the decisions that the EU must now take through the policies and initiatives currently in process. A key opportunity exists for societal and industrial transformation within the sustainability and safety ambitions that make Europe a global figurehead. \n\n\n\nThe agenda of the EFIB webinar 2025 is as follows: \n\n\n\n\nPresentation of the EFIB statement by our Director General\, Claire Skentelbery.\n\n\n\nPanel discussion with our wonderful participants.\n\n\n\nConfirmed Speakers\n\nMaarit Nyman – Senior Expert on Industrial Bioeconomy\, European Commission\n\n\n\nAna Maria Bravo – Director of Government Affairs\, IFF\n\n\n\nSaskia Kliphuis-Schotsman – Public Affairs Manager\, Corbion\n\n\n\nMonica Christensen – Senior Public Affairs Manager\, Novonesis\n\n\n\n\n\n\nThis will be followed by a short Q&A session. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/efib-brussels-statement-a-competitive-future-for-the-eu/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/04/Event-Banners-Website-19.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250402T120000
DTEND;TZID=Europe/Brussels:20250402T130000
DTSTAMP:20260726T155015
CREATED:20250307T125629Z
LAST-MODIFIED:20250307T130948Z
UID:8854-1743595200-1743598800@www.europabio.org
SUMMARY:A Biotech & Life-Sciences Roadmap: how investment can reach European Start-ups and Scale-ups?
DESCRIPTION:Europe is set for a wave of long-awaited policy action in the biotech and life sciences sectors – including through a European Startup and Scaleup Strategy\, a Life Sciences Strategy\, and a Biotech Act. \n\n\n\nMarking Poland’s Council Presidency of the European Union\, EuropaBio National Associations Council is excited to bring you the latest edition of its usual Council Presidency Summit! \n\n\n\nThis time\, in person in Warsaw\, in an informal setting\, we will explore the key elements of a successful national strategy for the life sciences sector and how Europe can better support its startups and scaleups to make them globally competitive. We will also explore how to bridge Eastern Europe and the Baltic nations with Western Europe\, building a truly single market for biotech and life sciences products. \n\n\n\nThis discussion will be co-hosted with the Polish biotechnology association BioForum. It will be part of its upcoming CEBioForum event 2025. \n\n\n\nIf you wish for further information\, and you will be attending CEBioForum\, feel free to drop a message to José Peres at j.peres@europabio.org. \n\n\n\nLocation: CIC\, Chmielna 73\, Warsaw\, Poland. \n\n\n\n\nMore info here
URL:https://www.europabio.org/event/a-biotech-life-sciences-roadmap-how-investment-can-reach-european-start-ups-and-scale-ups/
CATEGORIES:EuropaBio,National Associations
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2025/03/EuropaBio-Event-Banner-Templates-2-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250311T083000
DTEND;TZID=Europe/Brussels:20250313T173000
DTSTAMP:20260726T155015
CREATED:20240710T134750Z
LAST-MODIFIED:20240910T125522Z
UID:8038-1741681800-1741887000@www.europabio.org
SUMMARY:EFIB at BIOKET 2025
DESCRIPTION:The Bioeconomy’s Key Enabling Technologies Conference & Exhibition \n\n\n\nEuropaBio is thrilled to announce that the European Forum for Industrial Biotechnology (EFIB)\, and ACDV are joining forces with BIOKET 2025 in Brussels from March 11-13. This collaboration brings a significant policy-making component to our event\, providing an unparalleled opportunity to shape the bioeconomy sector’s future. \n\n\n\nJoin us on March 11th for an impactful Open Plenary Session dedicated to Policy Makers:  \n\n\n\nBiotechnology & Biomanufacturing for Europe: Building a critical EU future \n\n\n\n\n\n\n\nBiotechnology and Biomanufacturing are changing industrial ecosystems within a global race to establish resilient supply chains and competitive positions. BIOKET arrives at the heart of Europe with the technologies that drive progress and the companies that deliver outcomes. Our opening plenary will address EU ambition\, industrial strategy and the framework needed for Europe to play its full role on the world stage and shape a competitive and resilient future for the European and global bioeconomy. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/efib-at-bioket-2025/
CATEGORIES:EFIB,EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2024/07/Resize-image-project.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250129T183000
DTEND;TZID=Europe/Brussels:20250129T203000
DTSTAMP:20260726T155015
CREATED:20241217T125548Z
LAST-MODIFIED:20250128T102313Z
UID:8543-1738175400-1738182600@www.europabio.org
SUMMARY:A Driver of European Competitiveness: The Future of European Biotech
DESCRIPTION:EuropaBio\, the European association representing Bioindustries\, will host an evening reception co-hosted by MEP Stine Bosse (Vice-Chair\, SANT) and MEP Eszter Lakos (Member\, ITRE)\, to discuss the role of the European biotech sector in making the European industry more competitive. \n\n\n\nAmbassador Søren Jacobsen\, Deputy Permanent Representative of Denmark to the EU\, and Kristin Schreiber\, Director at DG GROW\, Klaus Berend\, Director SANTE will share some remarks on their approach to the biotech sector in the new mandate. \n\n\n\nThis event is only open to EuropaBio members & invited guests\, to find out more about EuropaBio membership\, contact us through our website here.
URL:https://www.europabio.org/event/a-driver-of-european-competitiveness-the-future-of-european-biotech/
CATEGORIES:Biomanufacturing Platform,EuropaBio,Healthcare Biotech,Industrial Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/12/EUROPABIO.6788f179502696.54888785.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20250128T140000
DTEND;TZID=Europe/Brussels:20250128T180000
DTSTAMP:20260726T155015
CREATED:20241126T083629Z
LAST-MODIFIED:20241126T083631Z
UID:8485-1738072800-1738087200@www.europabio.org
SUMMARY:EU Health Summit
DESCRIPTION:Healthy populations are essential for Europe to achieve its vision of a secure\, competitive\, and prosperous continent. Yet\, European health systems are navigating a perfect storm: ageing populations\, rising chronic diseases\, and a health workforce under strain. European societies are facing combined cost-of-living\, geopolitical\, and climate crises with significant implications for healthcare. \n\n\n\nAmid these challenges\, we must not lose sight of the extraordinary era we are living in—one of rapidly advancing science and innovation\, transforming health and unlocking new possibilities for Europe’s present and future generations. \n\n\n\nKeeping the health sector high on the political agenda is essential for the well-being of Europeans\, a resilient workforce\, the growth of the EU economy\, and the security of Europe. This is why\, during this EU mandate\, we need a robust and integrated strategy for health policy. \n\n\n\nWhat needs to be done in practice? \n\n\n\nJoin the EU Health Summit on 28 January to help shape a roadmap for a healthier Europe. \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/eu-health-summit/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/11/External-Events-Banners-600-×-200px-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241119T000000
DTEND;TZID=Europe/Brussels:20241119T235959
DTSTAMP:20260726T155015
CREATED:20241029T130646Z
LAST-MODIFIED:20241030T124012Z
UID:8442-1731974400-1732060799@www.europabio.org
SUMMARY:SME roundtable: Towards globally competitive European SMEs
DESCRIPTION:Europe is home to a vibrant community of Biotechnology SMEs contributing to the modernisation of the European industry. European biotechnology SMEs are the main drivers for innovation in healthcare\, food and feed\, industrial processes and manufacturing. \n\n\n\nThe Initiative on “Boosting Biotechnology and Biomanufacturing in the EU” published by the European Commission in March 2024 provides great prospects for EU SMEs. It highlights the EU ambition to deliver the benefits of biotechnology to support EU competitiveness and innovation alongside other global regions. One objective of the initiative is to identify ways to streamline EU legislation and its implementation to reduce Single Market fragmentation\, explore potential simplification of regulatory processes\, and shortening the time to market of biotechnological innovations. \n\n\n\nIn order to meet this objective\, EuropaBio\, the voice of biotechnology industries in Europe\, will be hosting this roundtable to work as partners with all relevant stakeholders to guarantee the success of this Initiative. This roundtable session aims to provide a discussion forum for SME participants active in the sector to share their main driving forces and obstacles to accessing global markets and supply chains. The session will explore the essential elements required to speed up EU market access of biotech products.  \n\n\n\nThis event will be followed by a dedicated report exploring the sessions outcomes. \n\n\n\nFor more information\, contact: communications@europabio.org
URL:https://www.europabio.org/event/sme-roundtable-towards-globally-competitive-european-smes/
CATEGORIES:EFIB,EuropaBio,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/10/External-Events-Banners-600-×-200px-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20241001T170000
DTEND;TZID=Europe/Brussels:20241001T200000
DTSTAMP:20260726T155015
CREATED:20240517T115325Z
LAST-MODIFIED:20240517T115327Z
UID:7794-1727802000-1727812800@www.europabio.org
SUMMARY:Europe's Biotechnology & Biomanufacturing Future
DESCRIPTION:Biotechnology is a critical technology for global economic security\, health and sustainability. \n\n\n\nEurope’s world-leading research is translated into medicines\, food and next generation biomanufacturing across sectors in all European regions\, with employment\, skills and economic growth as part of a more sustainable\, healthy\, autonomous and competitive Europe. \n\n\n\nThe importance of biotechnology to Europe is now recognised through multiple actions. The European Commission Initiative “Boosting Biotechnology and Biomanufacturing in the EU” highlights the EU ambition to deliver biotechnology for competitiveness and societal impact alongside fast moving global regions\, whilst the Letta report highlights its significance within a well-functioning single market. It is amplified further through its specific inclusion in legislations such as STEP and the Net Zero Industry Act. \n\n\n\nEuropaBio\, the voice of biotechnology industries in Europe\, will be hosting this reception to explore how biotechnology is used across sectors. Invited guests will meet the European innovators that deliver and use biotechnology and understand how it benefits the quality of life of all EU citizens. \n\n\n\nInnovative companies plus national and regional biotechnology associations will share their knowledge\, and guests will network across EU Institutions and other key stakeholders to discover how the European Union builds the future of biotechnology. \n\n\n\nFor more information\, contact: communications@europabio.org
URL:https://www.europabio.org/event/europes-biotechnology-biomanufacturing-future/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/05/Event-Banner-for-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240930T140000
DTEND;TZID=Europe/Brussels:20240930T160000
DTSTAMP:20260726T155015
CREATED:20240719T161756Z
LAST-MODIFIED:20240927T055832Z
UID:8081-1727704800-1727712000@www.europabio.org
SUMMARY:How does a Novel Food get to your plate?
DESCRIPTION:This EuropaBio’s webinar will focus on the pathway to market for Novel Foods\, from initial development in R&D through to consumer uptake while going through risk assessment and approval. Each speaker will cover a key point along the value chain\, including illustrative examples and case studies where relevant.    \n\n\n\nThe event will be moderated by Hannah Lester\, CEO at Atova Consulting.  \n\n\n\nThe confirmed speakers are: \n\n\n\n\nMuriel Dewilde\, Business Development Manager\, Bio Base Europe Pilot Plant\n\n\n\nErmolaos Ververis\, Scientific Officer Nutrition & Food Innovation Unit\, EFSA\n\n\n\nTimen Van Haaster\, Public Affairs & Communications Director\, HollandBio\n\n\n\nAnders Nelving\, Line Solution Manager\, Tetra Pak\n\n\n\nPer Falholt\, CSO at 21st Bio\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/how-does-a-novel-food-get-to-your-plate/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2024/07/banner-website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240924T140000
DTEND;TZID=Europe/Brussels:20240924T153000
DTSTAMP:20260726T155015
CREATED:20240604T072713Z
LAST-MODIFIED:20240919T083820Z
UID:7902-1727186400-1727191800@www.europabio.org
SUMMARY:The Future of Biotech: The Role of Legislation within Investment for Innovation
DESCRIPTION:To celebrate the start of European Biotech Week 2024\, EuropaBio is organising a webinar to discuss the critical intersection of legislation and investment into innovation within the biotech industry. With clear political support for European leadership in biotech\, ensuring EU legislation become key enabler of investment for innovation will be essential to the EU’s global competitiveness and strategic open autonomy. \n\n\n\nThis webinar will bring together representatives from the biotech industry\, investor community\, and European institutions to explore the essential elements required to foster a thriving biotech and life sciences ecosystem in the EU. \n\n\n\nThe confirmed speakers and full agenda are: \n\n\n\nWelcome and introduction  \n\n\n\nMarica Nobile (Assobiotec Federchimica) \n\n\n\nKeynote speech: EU biotech & biomanufacturing initiative  \n\n\n\nHans Ingels (DG GROW) \n\n\n\nPanel: Impact of EU Legislation on Investment Opportunities  \n\n\n\nYordan Aleksandrov (Pfizer) \n\n\n\nSME – Anna Handschuh (Future Affairs) \n\n\n\nNicoló Giacomuzzi-Moore (CBEJU) \n\n\n\nKatrien Swerts (Kurma Partners) \n\n\n\nMarica Nobile (Assobiotec Federchimica) will moderate the panel and deliver closing remarks. \n\n\n\n \n\n\n\n \n\n\n\n\nRegister Here
URL:https://www.europabio.org/event/the-future-of-biotech-the-role-of-legislation-on-investment-for-innovation/
CATEGORIES:Biotech Week,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/06/GENERAL.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240626T170000
DTEND;TZID=Europe/Brussels:20240626T190000
DTSTAMP:20260726T155015
CREATED:20240429T092024Z
LAST-MODIFIED:20240513T092250Z
UID:7743-1719421200-1719428400@www.europabio.org
SUMMARY:NAC Belgian Presidency Summer Reception
DESCRIPTION:EuropaBio\, bio.be/essenscia\, and flanders.bio biotechnology associations are organising a summer reception in Brussels for its members and invited guests to mark the end of the Belgium Council Presidency of the European Union and celebrate what best is made in Belgium – (beyond waffles and beers)\, biotechnology! \n\n\n\nWe will present the outcomes of our National Associations Council Presidency Summit “Made in Belgium for Europe“\, with recommendations on advanced therapies for rare diseases and microorganisms’ role in agricultural applications.  \n\n\n\nIf you wish for more details\, please reach out to communications@europabio.org
URL:https://www.europabio.org/event/nac-belgian-presidency-summer-reception/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-1-NAC-RECEPTION.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240507T140000
DTEND;TZID=Europe/Brussels:20240507T150000
DTSTAMP:20260726T155015
CREATED:20240429T082059Z
LAST-MODIFIED:20240429T084605Z
UID:7736-1715090400-1715094000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit - Report Launch
DESCRIPTION:“Policy pathways for biomanufacturing in Europe” was the theme of the Biomanufacturing Policy Summit 2024. The upcoming report will summarise the Summit’s keynote speeches and panel discussions and translate them into an analysis to Europe’s biomanufacturing strengths\, weaknesses\, opportunities and threats based on specific policies and industrial examples. \n\n\n\nThe report launch will also feature speakers who will respond to the report’s main conclusions and comment on their alignment with current challenges and future goals. \n\n\n\n\nHanna Freienstein\, Policy Officer\, DG GROW – European Commission\n\n\n\n⁠Jérôme Fabiano\, Deputy Director & Corporate Affairs Director\, EIT Health France\n\n\n\n⁠Per Falholt\, Chief Science Officer\, 21st.BIO\n\n\n\n\nThe boost to biotech and biomanufacturing needs a strong knowledge-based approach and the upcoming report aims to contribute to the discussion. Do not miss the opportunity and be up to date about biomanufacturing in Europe.
URL:https://www.europabio.org/event/europabios-biomanufacturing-policy-summit-report-launch/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/04/Untitled-600-x-200-px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240416T083000
DTEND;TZID=Europe/Brussels:20240416T120000
DTSTAMP:20260726T155015
CREATED:20240326T082922Z
LAST-MODIFIED:20240326T083218Z
UID:7614-1713256200-1713268800@www.europabio.org
SUMMARY:RARE DISEASES FORUM 2024
DESCRIPTION:Against the backdrop of the Belgian EU Council Presidency\, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations\, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. \n\n\n\n \n\n\n\nAbout ‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences\, fostering investment in the rare diseases sector\, and examining the benefits of a competitive agenda for those with rare diseases.  \n\n\n\nThe event is convened by Global Counsel on behalf of the forum partners\, EURORDIS\, RaDiOrg\, EFPIA\, Eucope\, EuropaBio\, Pharma.be\, UCB\, Novo Nordisk\, Sanofi & Takeda.
URL:https://www.europabio.org/event/rare-diseases-forum-2024/
CATEGORIES:EuropaBio,External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/03/Event-Banner-Website-updated.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240319T143000
DTEND;TZID=Europe/Brussels:20240319T164500
DTSTAMP:20260726T155015
CREATED:20240213T092326Z
LAST-MODIFIED:20240213T093923Z
UID:7402-1710858600-1710866700@www.europabio.org
SUMMARY:Industrial biotech: Is Europe ready to harness its potential?
DESCRIPTION:A Science | Business closed-door roundtable\, organised in partnership with EuropaBio – followed by networking reception \n\n\n\nOnly By Invitation \n\n\n\n \n\n\nBackground Information \nIn recent years industrial biotechnology – also known as “white” biotech – has emerged as a high-value driver of industrial modernisation and the green transition. Through the innovative use of microorganisms and enzymes\, it has transformative potential for manufacturing\, waste use and the creation of sustainable products in sectors as varied as energy\, textiles\, plastics\, paper\, agriculture and water. While some core processes\, such as fermentation technology\, have been commercially deployed for around 50 years\, the speed of scientific progress and solution development are accelerating exponentially. As such\, it appears that the sector as a whole is truly poised to make the leap from “proof of concept” to mainstream application at the European level.  \nThese take on greater importance when one considers other strategic priorities for the EU. First\, it is clear that for Europe to achieve e.g. its 2030 benchmark for net-zero technology manufacturing in the Green Deal Industrial Plan (GDIP)\, it will need to leverage its full innovation capacity across sectors. Second\, as global demand grows for sustainable solutions to climate\, energy\, biodiversity and food system crises\, Europe is ideally positioned to take market leadership in various domains\, given its research excellence and strong industrial base. And third\, the EU’s proposed Strategic Technologies for Europe Platform (STEP) has already identified biotechnologies among its key value chains to ensure future resilience\, autonomy and competitiveness\, while biotechnology has also been recognised as a critical technology for Europe. \nYet a degree of skepticism remains – both in public and policy circles – about the risk/reward ratio of biotechnologies and their wider value to society. One useful counterpoint is to consider the evolution of health-related biotechnology (often called “red” biotech). Having overcome similar resistance and concerns\, “red” biotech is now deployed at scale throughout the life science and pharmaceutical sectors\, and is acknowledged today as a key component in European health innovation. So how can the lessons learned on that journey be absorbed and applied to other sectors?   \n As the EU prepares for its transition to a new Parliament and Commission\, it is therefore an ideal moment to open a multistakeholder dialogue on how policy and regulatory innovations could increase the European added value of “white” biotech and biomanufacturing in the years to come. This also builds on Ursula von der Leyen’s announcement of a new biotech and biomanufacturing initiative in last September’s state-of-the-union address. Among some of the key issues for consideration: \nWhere can industrial biotech and biomanufacturing contribute most effectively to the GDIP and STEP\, and what are the longer-term implications for boosting the global competitiveness of European companies?\nWhat should underpin a future EU roadmap for advancing “white” biotech and biomanufacturing across sectors\, in line with other long-term strategies and objectives?\nWhich other steps are needed at EU and national level to build future capacity\, such as infrastructure and skills?\nIn which ways can public and private finance best support pioneering “white” biotech firms – large and small – in scaling up and maturing their solutions to market-readiness and mass production levels\, as has happened in the health sector?\nBeyond the CBE Joint Undertaking\, to what extent could Horizon Europe\, FP10 and other key instruments – such as the new biotech & biomanufacturing initiative – strengthen Europe’s industrial biotech R&D ecosystem in the next policy cycle?\nOn March 19\, Science|Business\, in cooperation with EuropaBio\, will convene a select group of senior figures and experts from across the industrial biotech spectrum to address these issues in a closed-door\, invitation-only roundtable. Drawing in part on latest research and real-world applications\, the meeting will identify recommendations to harness the full potential of “white” biotech and biomanufacturing\, and to align its further development with the realisation of key EU policy goals.\n \n \n\n\n\n\n\n\n \n\n\n\n \n\n\n\nFor more information\, please contact: denitsa.nikolova@sciencebusiness.ne \n\n\n\n \n\n\n\n \n\n\n\n\nClick here for more information
URL:https://www.europabio.org/event/industrial-biotech-is-europe-ready-to-harness-its-potential/
CATEGORIES:EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240313T130000
DTEND;TZID=Europe/Brussels:20240313T200000
DTSTAMP:20260726T155015
CREATED:20231213T100000Z
LAST-MODIFIED:20240209T113124Z
UID:7082-1710334800-1710360000@www.europabio.org
SUMMARY:Biomanufacturing Policy Summit 2024 - Policy pathways for biomanufacturing in Europe
DESCRIPTION:The Biomanufacturing Policy Summit will host its 2nd edition in March 2024. The invite-only half-day summit hosted by EuropaBio brings together stakeholders including industry representatives and policymakers\, to discuss Europe’s ambitions for biomanufacturing and the tangible legislative\, regulatory and strategic pathways. \n\n\n\n2023 was a year of visibility and recognition for biomanufacturing in Europe. It saw the creation of the Strategic Technologies for Europe Platform (STEP) and the announcement of the EU Biotech and Biomanufacturing Initiative\, plus the identification of biotechnology as a critical technology for Europe’s security. 2024 is expected to be a year in which initiatives gain policy momentum\, within a new Parliament and Commission and begin to deliver practical and impactful instruments to European industries. \n\n\n\n \n\n\n\n13:00 – Lunch14:00 – Welcome & Introduction14:10 – Keynote Speakers15:30 – Defragmenting and Accelerating Europe’s Biotech & Biomanufacturing – The Role of Policy “How does policy impact decisions for biomanufacturing companies in Europe across sectors?”16:15 – Coffee Break16:30 – Out of the Box – A Global View on Biomanufacturing Policies “What can Europe learn and lead from policy across global regions?”17:15 – How does Policy deliver for Biomanufacturing – Looking Ahead “The policy future for Europe\, with recommendations for the incoming Commission and Parliament.”18:00 – Networking Reception \n\n\n\n \n\n\n\nParticipants will discuss how policy enables Europe to seize the opportunity for biomanufacturing within innovative\, sustainable and critical products within global supply chains. The Summit will address policy pathways for how biotech and biomanufacturing can deliver results in competitiveness\, Green Transition and resilience across sectors. \n\n\n\nFor all enquiries\, please contact our Biomanufacturing Platform Coordinator\, Francisco Castro Alves: f.alves@europabio.org
URL:https://www.europabio.org/event/biomanufacturing-policy-summit-2024-policy-pathways-for-biomanufacturing-in-europe/
CATEGORIES:Biomanufacturing Platform,EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Event-Banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240307T130000
DTEND;TZID=Europe/Brussels:20240307T143000
DTSTAMP:20260726T155015
CREATED:20240209T095401Z
LAST-MODIFIED:20240306T151454Z
UID:7385-1709816400-1709821800@www.europabio.org
SUMMARY:EuropaBio Webinar – How will the revision EU General Pharmaceutical Legislation impact Europe’s innovation ecosystem and biotechnology companies?
DESCRIPTION:Join us on 7 March to discuss the impact of revision of the EU’s General Pharmaceutical Legislation (GPL) on Europe’s innovation ecosystem and biotechnology companies. \n\n\n\nFollowing the publication on 24 January 2024 of a new study analysing the expected impact of the GPL on the biotechnology innovation ecosystem\, EuropaBio is delighted to invite you to attend its exclusive webinar to discuss the consequences of this landmark legislation for the future of innovation in healthcare in Europe\, EU patients and economies within a global race towards health security and competitiveness. \n\n\n\nThe event will start with a presentation of the study by Charles Rivers Associates and will be followed by a panel discussion featuring leading voices of the European biotechnology ecosystem to discuss the impact of the proposed legislation and its consequences on the development of breakthrough medicines for EU patients. \n\n\n\nThe webinar will take place on Thursday 7 March at 13.00 CET. If you wish to attend\, please register below. \n\n\n\nAgenda: \n\n\n\n\nWelcome & Introduction: 13:00 – 13:05\, Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n\nReport Presentation and Q&A: 13:05 – 13:30\, Antun Sablek & Tim Wilsdon\, Charles River Associates\n\n\n\nPanel Discussion and Q&A: 13:30 – 14:25\, Panelists: John James Ricketts\, Noel Minnis\, Thomas Bols\, Tineke Van hooland\, Wojciech Nowak and Yordan Aleksandrov. Moderated by Dr Claire Skentelbery.\n\n\n\nConcluding Remarks: 14:25 – 14:30 Dr Claire Skentelbery\, Director General EuropaBio\n\n\n\n\n \n\n\n\nSpeakers: Moderated by Dr Claire Skentelbery\, EuropaBio \n\n\n\n\nAntun Sablek\, Charles River Associates\n\n\n\nJohn James Ricketts\, Eli Lilly\n\n\n\nNoel Minnis\, Takeda\n\n\n\nThomas Bols\, PTC Therapeutics\n\n\n\nTim Wilsdon\, Charles River Associates\n\n\n\nTineke Van hooland\, Bio.be\n\n\n\nWojciech Nowak\, Novartis\n\n\n\nYordan Aleksandrov\, Pfizer\n\n\n\n\n\nRegister here
URL:https://www.europabio.org/event/europabio-webinar-how-will-the-revision-eu-general-pharmaceutical-legislation-impact-europes-innovation-ecosystem-and-biotechnology-companies/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/02/CRA-Webinar-Banner-Event-Website.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240221T100000
DTEND;TZID=Europe/Brussels:20240221T120000
DTSTAMP:20260726T155015
CREATED:20231218T141335Z
LAST-MODIFIED:20240206T094606Z
UID:7206-1708509600-1708516800@www.europabio.org
SUMMARY:Made in Belgium for Europe\, National Associations' Council Presidency Summit
DESCRIPTION:Whether it’s microorganisms revolutionising manufacturing or advanced therapies for rare disease patients\, biotechnology is leading the way\, and Belgium is on it.  \n\n\n\nIf you are a researcher\, entrepreneur\, policy wonk\, or simply curious about the future of biotechnology\, join us in our free online conversation.  \n\n\n\nThis conversation will be public and held online on February 21\, 2024\, from 10:00 to 12:00. If you wish to attend our session\, please register. If you have any questions\, insights or suggestions\, do not hesitate to contact José Peres at j.peres@europabio.org. \n\n\n\n \n\n\n\n\nRegister here\n\n\n\n\n \n\n\n\n\nDownload the Agenda
URL:https://www.europabio.org/event/made-in-belgium-for-europe-national-associations-council-presidency-summit/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/12/Banner-Event-Website-4.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240124T120000
DTEND;TZID=Europe/Brussels:20240124T150000
DTSTAMP:20260726T155015
CREATED:20240109T104014Z
LAST-MODIFIED:20240116T095205Z
UID:7234-1706097600-1706108400@www.europabio.org
SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.  \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL?
URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/
CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231201T083000
DTEND;TZID=Europe/Brussels:20231201T094500
DTSTAMP:20260726T155015
CREATED:20231031T084455Z
LAST-MODIFIED:20231031T084520Z
UID:7041-1701419400-1701423900@www.europabio.org
SUMMARY:EFIB 2023 Rotterdam Statement wider launch
DESCRIPTION:Industrial biotechnology for a sustainable and resilient global Europe  \n\n\n\nAs the EU looks ahead to the European elections in 2024\, with a new EU Commission mandate and Work Programme\, EuropaBio reviews European strategies and ambitions where biotechnology plays a key role. Ursula von der Leyen’s State of the European Union address of 13 September announced an ‘EU Biotech and Biomanufacturing Initiative’. The announced EU initiative is the latest indication of a greater point of recognition and acceleration for biotechnology. \n\n\n\nBuilding on this momentum\, the EFIB Rotterdam Statement of 2023 provides a priority pathway for biotechnology to support Europe’s global leadership\, resilience and competitiveness. \n\n\n\nWe invite you to join us for a discussion on the role and potential of biotechnology and Europe’s global position in the context of the 2024 EU election. \n\n\n\n\nInvitation Only Event
URL:https://www.europabio.org/event/efib-2023-rotterdam-statement-wider-launch/
CATEGORIES:EFIB,EuropaBio,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Vilnius-Statement-Event-600-×-260px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231130T143000
DTEND;TZID=Europe/Brussels:20231130T160000
DTSTAMP:20260726T155015
CREATED:20231018T092656Z
LAST-MODIFIED:20231018T113625Z
UID:7003-1701354600-1701360000@www.europabio.org
SUMMARY:EuropaBio Patient BioForum 2023 Roundtable on Advancing Solutions for Unmet Medical Needs
DESCRIPTION:Hybrid Event | Invitation Only \n\n\n\n\n\nEuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. To address unmet medical needs (UMN)\, the Commission proposed as part of the revision of the EU General Pharmaceutical Legislation (GPL) to introduce a definition of UMN and a definition of high UMN. Under the Commission’s proposals\, all orphan products would qualify as addressing UMN but only a subset of products would meet the HUMN criteria. The Commission’s proposals on UMN and especially HUMN received mixed reactions from patient organisations and negative reactions from the industry. \n\n\n\nOn 1 December 2022\, EuropaBio organised a Patient BioForum which brought together industry and patient organisations to discuss the topic of UMN in view of reaching a common understanding on UMN. Those discussions revealed shared interests and concerns with the possible approach to UMN in the EU Pharmaceutical Legislation. The discussions were followed by a report which outlined recommendations to policymakers to enable Europe to address the challenge of UMN. \n\n\n\nWith the proposals now presented and being negotiated by the European Parliament and the Council\, the 2023 Patient BioForum is an opportunity to build on the 2022 Patient BioForum to foster exchanges between patient groups and industry on UMNs\, including expectations from the legislation and beyond. The 2023 Patient BioForum will also be an opportunity to issue multi-stakeholder recommendations to policymakers to ensure the GPL is fit for purpose to address patients need and support innovation.   \n\n\n\n \n\n\n\nProgramme \n\n\n\nThe 2023 Patient BioForum will be held in a roundtable format under Chatham House Rule. A wide range of stakeholders representing patients\, regulators\, policy-makers\, and industry will be invited to take part in the roundtable. All participants will be invited to take an active part in the discussion to bring their unique perspective. The roundtable will be followed by a report to summarise the discussions. \n\n\n\n1. Introductions \n\n\n\n2. Legislating Unmet Medical Needs: Perspectives from the European Commission and the European Parliament \n\n\n\n3. Roundtable topic 1:  How Can the EU Pharmaceutical Legislation Help Stimulate Patient-Centric Innovation? \n\n\n\n4. Roundtable topic 2: How can Europe Incentivise R&D for UMN and Underserved Areas? \n\n\n\n5. Conclusions \n\n\n\nIf you would like to attend\, please contact Adrian Lincoln\, a.lincoln@europabio.org
URL:https://www.europabio.org/event/europabio-patient-bioforum-2023-roundtable-on-advancing-solutions-for-unmet-medical-needs/
CATEGORIES:EuropaBio,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Event-Banners-Website-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231024T080000
DTEND;TZID=Europe/Brussels:20231025T170000
DTSTAMP:20260726T155015
CREATED:20230413T124141Z
LAST-MODIFIED:20230525T155522Z
UID:6110-1698134400-1698253200@www.europabio.org
SUMMARY:EFIB 2023 - Industrial biotechnology for a sustainable and resilient global Europe
DESCRIPTION:EuropaBio is pleased to announce that this year’s edition of EFIB\, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title ‘Industrial biotechnology for a sustainable and resilient global Europe’\, will take place 24-25 October 2023 in Rotterdam\, The Netherlands. EuropaBio is partnering with local hosts HollandBio and ChemistryNL to bring EFIB 2023 to Rotterdam. \n\n\n\nNow in its 16th year\, EFIB will be dedicated to exploring how industrial biotechnology and the bioeconomy supports European competitiveness. EFIB brings together professionals from across the value chain to discuss advancements from industrial biotechnology and its contribution towards positioning Europe as a global leader in addressing societal and sustainability challenges. Participants include industry of all sizes\, as well as the community that enables industry to deliver\, including researchers\, policy makers\, regulators\, and global organisations. \n\n\n\nOur two-day programme includes inspiring plenaries\, a start-up pitching hour and will explore our four thematic areas – Food\, Feed & Nutrition; Sustainable Biomaterials; Bioprocesses & Technologies; and Sustainable Finance – as well as new frontiers like biomanufacturing. The programme is complemented by the exhibition: including start-ups and SMEs in our SME Village\, the academic poster presentation in our Innovation Campus\, and exhibitors from industry and national associations. Interested in exhibiting? Check out our sponsorship page.   \n\n\n\nAttending EFIB 2023 will allow you to learn about the latest market trends and research findings in industrial biotechnology and network with key stakeholders.  \n\n\n\n\nRegister Here\n\n\n\n\nFor more information visit our website and subscribe to our newsletter.
URL:https://www.europabio.org/event/efib-2023-industrial-biotechnology-for-a-sustainable-and-resilient-global-europe/
CATEGORIES:EFIB
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/04/Copy-of-General-template-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20231011T133000
DTEND;TZID=Europe/Brussels:20231011T150000
DTSTAMP:20260726T155015
CREATED:20230920T110911Z
LAST-MODIFIED:20230920T110912Z
UID:6861-1697031000-1697036400@www.europabio.org
SUMMARY:SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs
DESCRIPTION:In April 2023\, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem. \n\n\n\nAs emerging and small companies have become innovation drivers\, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow\, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe. \n\n\n\nThis event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients\, assess the foreseeable impacts of the revision on those companies\, and hear directly from them what they need from the revision to continue their journey in Europe.
URL:https://www.europabio.org/event/smes-in-a-changing-world-the-impact-of-the-revision-of-the-pharmaceutical-legislation-on-europes-innovative-smes/
CATEGORIES:EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/09/Event-Banners-Website.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230627T180000
DTEND;TZID=Europe/Brussels:20230627T200000
DTSTAMP:20260726T155015
CREATED:20230524T142640Z
LAST-MODIFIED:20230616T172415Z
UID:6330-1687888800-1687896000@www.europabio.org
SUMMARY:NAC Spanish Presidency Summer Reception
DESCRIPTION:EuropaBio\, and AseBio\, the Spanish Association of Biotechnology Companies\, with the support of Merck\, will host a summer reception to mark the beginning of the Spanish Council Presidency of the European Union and present the outcomes of their National Association Council Presidency Summit.  \n\n\n\nThe event will take place on June 27th in Brussels at Comet Meetings – Louise\, from 18-20h. If you wish for more details\, please get in touch with José Peres at j.peres@europabio.org 
URL:https://www.europabio.org/event/nac-spanish-presidency-summer-reception/
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/NAC-Summer-Reception-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20230605T173000
DTEND;TZID=Europe/Brussels:20230605T183000
DTSTAMP:20260726T155015
CREATED:20230523T115247Z
LAST-MODIFIED:20230524T142835Z
UID:6282-1685986200-1685989800@www.europabio.org
SUMMARY:EuropaBio: BIO 2023
DESCRIPTION:Round table –Biomanufacturing for health: advancing healthcare and global preparedness \n\n\n\n\n\nEuropaBio is pleased to host a round table discussion at the upcoming BIO International Convention in Boston and invites all delegates to join us to discuss on biomanufacturing for health: advancing healthcare and global prepareness.  \n\n\n\nBiomanufacturing within healthcare represents an advance in therapeutic capabilities\, as ground-breaking research translates into increased diseases that can be targeted\, either for the first time or with greater efficacy\, with increasingly complex interventions becoming possible. It also brings resilience and increased environmental sustainability to strained supply chains as the world strives to modernise production systems. \n\n\n\nThe transition has significant implications for global healthcare\, competitiveness\, sustainability and resilience\, with capacity building important in all regions. \n\n\n\nThis is not just reflected in advancing healthcare for citizens but also for the world’s ability to respond to healthcare crises.  Covid demonstrated that  biomanufacturing capacity globally was called into action from multiple applications and countries for the complex manufacturing process behind vaccines. \n\n\n\nThis biomanufacturing capacity does not exist within a vacuum\, ready to be called to action when needed. It requires drug developers large and small\, public and private\, specialised manufacturers\, plus skills base\, supply chain and logistics frameworks resulting from significant investment over many years. \n\n\n\nImportantly\, a sustainable biomanufacturing framework is financed and delivered primarily through industry\, meaning that is must be integral to company strategy. This is not a guarantee\, as the global healthcare industry reacts to legislative changes and government strategies\, with major investment decisions having long term implications for the capacity and skills base within countries and regions. \n\n\n\nWhat does the world need to get right to ensure that biomanufacturing capacity grows\, to serve patients with advancing therapies and be there for coordinated emergency responses? \n\n\n\nParticipants within the round table reflect global biomanufacturing stakeholders and will discuss: \n\n\n\n\nNational policies\, incentives and strategy\n\n\n\nRegulatory and standards and alignment\n\n\n\nInternational cooperation and development\n\n\n\n\nThe output from this roundtable will be a call to global action for biomanufacturing published through EuropaBio and BIO\, with all delegates invited to contribute through the round table and follow up. \n\n\n\nAgenda \n\n\n\n10:30Welcome and introductionEuropaBio and BIO10:40Setting the scene for global biomanufacturing and the planned outcome from the round tableClaire10:45(draft) Discussion points for participants: – What does your country need to achieve for resilience through national or accessible biomanufacturing capacity?– How are regulatory frameworks adapting to an increasingly biological pipeline of medicines?– What does international cooperation need to achieve to ensure that manufacturing is actually possible during pandemic responses?– Name a priority for you to reach biomanufacturing goals in the coming years.All participants: Lead interventions on specific topics11:30Closing remarksEuropaBio and BIO\n\n\n\n\n\n\n\n \n\n\n\n\nMore information here
URL:https://www.europabio.org/event/europabio-bio-2023/
LOCATION:Boston Convention & Exhibition Center\, Boston\, Massachusetts\, United States
CATEGORIES:EuropaBio
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/Event-Banners-Website.jpg
END:VEVENT
END:VCALENDAR